Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...

A one-time subretinal injection of Sura-vec at both high- and low-dose concentrations allowed more than half of patients with ...

While anti-VEGF therapies remain the current standard of care, many DME patients experience suboptimal responses due to ...

Aging Therapies SINGAPORE, SG / ACCESS Newswire / October 22, 2025 / Immortal Dragons, a $40 million longevity fund, announced its strategic investment in Unlimited Bio, a biotechnology company ...

If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.

In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in significant progression-free survival improvements, it fell short of the ...

Retail buzz around Summit Therapeutics picked up Sunday after the biotech reported what it called a first-of-its-kind result in a major lung cancer study, showing that its experimental antibody ...

GLP-1 receptor agonists and fenofibrate medications significantly reduced the risk for developing diabetic macular edema, ...

CStone Pharmaceuticals (CStone, HKEX: 2616),  an innovation-driven biopharmaceutical company focused on the research and ...

This comprehensive presentation examines complex retinal disease management using sequential anti-VEGF therapies, supported ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October ...

University of Bristol researchers have discovered a VEGF-C gene therapy that protects the kidneys in people with type 1 ...